Longchuan Bai
Overview
Explore the profile of Longchuan Bai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1812
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rej R, Hu B, Chen Z, Acharyya R, Wu D, Metwally H, et al.
J Med Chem
. 2024 Nov;
67(23):20933-20965.
PMID: 39585895
Inhibition of estrogen receptor alpha (ERα) signaling is an established therapeutic approach for the treatment of ER-positive (ER+) breast cancers, but new therapeutic strategies are urgently needed to overcome clinical...
2.
Xu R, Zhou H, Bai L, McEachern D, Wu D, Acharyya R, et al.
J Med Chem
. 2024 Nov;
67(22):20495-20513.
PMID: 39509603
STAT3 is an attractive therapeutic target for cancer and other human diseases. We have previously reported the discovery of potent, selective, and efficacious PROTAC STAT3 degraders SD-36 and SD-91. In...
3.
Acharyya R, Rej R, Hu B, Chen Z, Wu D, Lu J, et al.
J Med Chem
. 2024 Nov;
67(21):19010-19037.
PMID: 39485242
Despite the development of highly effective therapies for the treatment of estrogen receptor α (ERα)-positive human breast cancer, clinical resistance to current therapies requires the development of novel therapeutic strategies....
4.
Kaneshige A, Yang Y, Bai L, Wang M, Xu R, Mallik L, et al.
J Med Chem
. 2024 Sep;
68(5):5125-5151.
PMID: 39311434
STAT6 is an attractive therapeutic target for human cancers and other human diseases. Starting from a STAT6 ligand with = 3.5 μM binding affinity, we obtained AK-068 with = 6...
5.
Wang C, Wang M, Wang Y, Rej R, Aguilar A, Xu T, et al.
J Med Chem
. 2024 Aug;
67(16):14125-14154.
PMID: 39132814
The bromodomain-containing protein BRD9 has emerged as an attractive therapeutic target. In the present study, we successfully identified a number of highly potent BRD9 degraders by using two different cereblon...
6.
Krempski J, Yamani A, Thota L, Marella S, Ganesan V, Sharma A, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):719-734.
PMID: 38777155
Background: Mast cell-derived mediators induce vasodilatation and fluid extravasation, leading to cardiovascular failure in severe anaphylaxis. We previously revealed a synergistic interaction between the cytokine IL-4 and the mast cell-derived...
7.
Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, et al.
J Med Chem
. 2024 Mar;
67(7):5351-5372.
PMID: 38530938
CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are promising cancer therapeutic targets. Herein, we report the discovery of highly potent, selective, and orally bioavailable CBP/p300 degraders...
8.
Chen Z, Wang M, Wu D, Bai L, Xu T, Metwally H, et al.
J Med Chem
. 2024 Mar;
67(7):5275-5304.
PMID: 38477974
CBP/p300 proteins are key epigenetic regulators and promising targets for the treatment of castration-resistant prostate cancer and other types of human cancers. Herein, we report the discovery and characterization of...
9.
Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, et al.
J Med Chem
. 2023 Sep;
66(18):13280-13303.
PMID: 37683104
We report herein the discovery and extensive characterization of ARD-1676, a highly potent and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was designed using a new class...
10.
Chen Z, Hu B, Rej R, Wu D, Acharyya R, Wang M, et al.
J Med Chem
. 2023 Aug;
66(17):12559-12585.
PMID: 37647546
Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast cancer. Despite the development of several effective therapies targeting ERα signaling, clinical resistance remains a...